School of Medicine (J.W.B., R.J.F., S.C.L., A.R., J.R.L., G.F.W., C.J.S.), University of Western Australia, Perth.
Department of Cardiology (J.W.B., S.C.L., A.R., C.J.S.), Department of Cardiology, Royal Perth Hospital, Perth, Western Australia.
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):534-541. doi: 10.1161/ATVBAHA.120.315364. Epub 2020 Dec 3.
The coronary calcium score (CCS) predicts cardiovascular disease risk in individuals with diabetes, and rate of progression of CCS is an additional and incremental marker of risk. F-sodium fluoride positron emission tomography (F-NaF PET) detects early and active calcifications within the vasculature. We aimed to ascertain the relationship between F-NaF PET activity and CCS progression in patients with diabetes. Approach and Results: We identified individuals between 50 and 80 years with diabetes and no history of clinical coronary artery disease. Those with a CCS ≥10 were invited to undergo F-NaF PET scanning and then repeat CCS >2 years later. F-NaF PET and CCS analysis were performed on a per-coronary and a per-patient level. We compared the proportion of CCS progressors in F-NaF PET-positive versus F-NaF PET-negative coronary arteries. Forty-one participants with 163 coronary arteries underwent follow-up CCS 2.8±0.5 years later. F-NaF PET-positive coronary arteries (n=52) were more likely to be CCS progressors, compared with negative coronary arteries (n=111; 86.5% versus 52.3%, <0.001). Adjusting for baseline CCS, F-NaF PET-positive disease was an independent predictor of subsequent CCS progression (odds ratio, 2.92 [95% CI, 1.32-6.45], =0.008). All subjects (100%, 15/15) with ≥2 F-NaF-positive coronary arteries progressed in CCS.
In subjects with diabetes, F-NaF PET positivity at baseline, independently predicted the progression of calcifications within the coronary arteries 2.8 years later. These findings suggest F-NaF PET may be a promising technique for earlier identification of patients at higher risk of cardiovascular events.
冠状动脉钙评分(CCS)可预测糖尿病患者的心血管疾病风险,而 CCS 的进展速度是风险的额外且递增的标志物。氟[F]-钠氟化钠正电子发射断层扫描(F-NaF PET)可检测血管内的早期和活跃钙化。我们旨在确定糖尿病患者中 F-NaF PET 活性与 CCS 进展之间的关系。方法和结果:我们确定了年龄在 50 岁至 80 岁之间且无临床冠状动脉疾病史的糖尿病患者。CCS≥10 的患者被邀请接受 F-NaF PET 扫描,然后在 2 年以上时间后再次进行 CCS 检查。在冠状动脉和患者两个层面上进行 F-NaF PET 和 CCS 分析。我们比较了 F-NaF PET 阳性和 F-NaF PET 阴性冠状动脉中 CCS 进展者的比例。41 名参与者的 163 支冠状动脉在 2.8±0.5 年后进行了后续 CCS 检查。与阴性冠状动脉(n=111;86.5%比 52.3%,<0.001)相比,F-NaF PET 阳性冠状动脉(n=52)更有可能是 CCS 进展者。调整基线 CCS 后,F-NaF PET 阳性疾病是随后 CCS 进展的独立预测因子(比值比,2.92[95%CI,1.32-6.45],=0.008)。所有(100%,15/15)基线时至少有 2 个 F-NaF 阳性冠状动脉的患者 CCS 均有进展。结论:在糖尿病患者中,基线 F-NaF PET 阳性独立预测了 2.8 年后冠状动脉内钙化的进展。这些发现表明,F-NaF PET 可能是一种有前途的技术,可更早识别心血管事件风险较高的患者。